Biocon Malaysia Secures UK MHRA Approval for Semglee Fill-Finish Unit
Biocon Ltd 路 Others (Uncategorized) 路 25 Sept 2026, 2:03 pm
Biocon Malaysia Secures UK MHRA Approval for Semglee Fill-Finish Unit Biocon Limited announced on 25th Sep'26 that its Malaysian insulin manufacturing facility received UK MHRA approval for its new drug product fill-finish unit for Semglee (insulin glargine). This follows an earlier regulatory clearance obtained from the European Medicines Agency (EMA) in Jul'26 for the same fill-finish line, strengthening the company's global supply capabilities for European and UK markets.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 18 Nov 2026
- Press Release 路 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
